Increased expression levels of vitronectin in the maternal‑fetal interface of placenta in early-onset severe preeclampsia

Shen,Jing; Ma,Xiaoyan; Yi,Fei; Rasul,Azhar; Cui,Manhua; Ma,Tonghui

doi:10.3892/mmr.2012.1141

Increased expression levels of vitronectin in the maternal‑fetal interface of placenta in early-onset severe preeclampsia

Authors:
- Jing Shen
- Xiaoyan Ma
- Fei Yi
- Azhar Rasul
- Manhua Cui
- Tonghui Ma
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, Jilin University Bethune Second Hospital, Changchun 130041, P.R. China, Central Research Laboratory, Jilin University Bethune Second Hospital, Changchun 130041, P.R. China
Published online on: October 22, 2012 https://doi.org/10.3892/mmr.2012.1141
Pages: 53-58

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Preeclampsia (PE) is a pregnancy-specific disease, the pathogenesis of which remains unclear. The present study was designed to analyze whether vitronectin (VN), a multifunctional human glycoprotein, is expressed in PE and normal placentas. Furthermore, we aimed to explore VN expression profiles in relation to the pathogenesis of PE. Placental samples and plasma of early-onset severe PE (EOSP), late-onset severe PE (LOSP) and 2 control groups corresponding to EOSP and LOSP were collected. Immunohistochemistry, immunofluorescence and western blot analysis were used to detect VN protein expression profiles. mRNA expression levels of VN were detected by reverse transcription polymerase chain reaction (RT-PCR). The impact of VN on coagulation was investigated by comparing differences in coagulation parameters. Our results demonstrate that expression levels of VN in the maternal-fetal interface of the EOSP group are the highest (P<0.001). The expression levels of VN in descending order in infarct center, infarct edge, near infarct tissues and away from infarct tissues were identified (P<0.001). Immunofluorescence and immunoblotting were consistent with immunohistochemical results. The VN mRNA expression was detected. Prothrombin time (PT) was significantly shorter in EOSP compared with the control group (P<0.05), which had a significant negative correlation with expression levels of VN in the placental tissue of the group. VN may play a key role in repairing the lesions and limiting necrotic components into maternal blood through its adhesion. VN may be involved in the pathogenesis of EOSP by inducing an imbalance between coagulation and fibrinolysis.

View Figures

View References

1	Marzioni D, Todros T, Cardaropoli S, et al: Activating protein-1 family of transcription factors in the human placenta complicated by preeclampsia with and without fetal growth restriction. Placenta. 31:919–927. 2010. View Article : Google Scholar : PubMed/NCBI
2	Lindheimer MD, Taler SJ and Cunningham FG: Hypertension in pregnancy. J Am Soc Hypertens. 2:484–494. 2008. View Article : Google Scholar
3	World Health Organization (WHO). Attending to 136 million births, every year. The World Health Report 2005: Make Every Mother and Child Count. 1st edition. WHO Press; Geneva, Switzerland: pp. 642005
4	Blumenstein M, Prakash R, Cooper GJ and North RA: Aberrant processing of plasma vitronectin and high-molecular-weight kininogen precedes the onset of preeclampsia. Reprod Sci. 16:1144–1152. 2009. View Article : Google Scholar : PubMed/NCBI
5	Chanprapaph P: Update in pre-eclampsia. J Med Assoc Thai. 87(Suppl 3): S104–S112. 2004.PubMed/NCBI
6	Alanis MC, Robinson CJ, Hulsey TC, Ebeling M and Johnson DD: Early-onset severe preeclampsia: induction of labor vs elective cesarean delivery and neonatal outcomes. Am J Obstet Gynecol. 199:262.e1–262.e6. 2008. View Article : Google Scholar : PubMed/NCBI
7	Aris A, Benali S, Ouellet A, Moutquin JM and Leblanc S: Potential biomarkers of preeclampsia: inverse correlation between hydrogen peroxide and nitric oxide early in maternal circulation and at term in placenta of women with preeclampsia. Placenta. 30:342–347. 2009. View Article : Google Scholar
8	Wang AG, Yen MY, Hsu WM and Fann MJ: Induction of vitronectin and integrin alphav in the retina after optic nerve injury. Mol Vis. 12:76–84. 2006.PubMed/NCBI
9	Singh B, Su YC and Riesbeck K: Vitronectin in bacterial pathogenesis: a host protein used in complement escape and cellular invasion. Mol Microbiol. 78:545–560. 2010. View Article : Google Scholar : PubMed/NCBI
10	Lam C, Lim KH and Karumanchi SA: Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension. 46:1077–1085. 2005. View Article : Google Scholar : PubMed/NCBI
11	Keeton M, Eguchi Y, Sawdey M, Ahn C and Loskutoff DJ: Cellular localization of type 1 plasminogen activator inhibitor messenger RNA and protein in murine renal tissue. Am J Pathol. 142:59–70. 1993.PubMed/NCBI
12	Tedesco F, Radillo O, Candussi G, Nazzaro A, Mollnes TE and Pecorari D: Immunohistochemical detection of terminal complement complex and S protein in normal and pre-eclamptic placentae. Clin Exp Immunol. 80:236–240. 1990. View Article : Google Scholar : PubMed/NCBI
13	Rasul A, Yu B, Khan M, et al: Magnolol, a natural compound, induces apoptosis of SGC-7901 human gastric adenocarcinoma cells via the mitochondrial and PI3K/Akt signaling pathways. Int J Oncol. 40:1153–1161. 2012.PubMed/NCBI
14	Rasul A, Yu B, Zhong L, Khan M, Yang H and Ma T: Cytotoxic effect of evodiamine in SGC-7901 human gastric adenocarcinoma cells via simultaneous induction of apoptosis and autophagy. Oncol Rep. 27:1481–1487. 2012.PubMed/NCBI
15	James JL, Whitley GS and Cartwright JE: Pre-eclampsia: fitting together the placental, immune and cardiovascular pieces. J Pathol. 221:363–378. 2010. View Article : Google Scholar : PubMed/NCBI
16	Redman CW and Sargent IL: Latest advances in understanding preeclampsia. Science. 308:1592–1594. 2005. View Article : Google Scholar : PubMed/NCBI
17	Vedin JA, Wilhelmsson CE and Werkö L: Comparative study of alprenolol and methyldopa in previously untreated essential hypertension. Br Heart J. 35:1285–1292. 1973. View Article : Google Scholar : PubMed/NCBI
18	Egbor M, Ansari T, Morris N, Green CJ and Sibbons PD: Morphometric placental villous and vascular abnormalities in early- and late-onset pre-eclampsia with and without fetal growth restriction. BJOG. 113:580–589. 2006. View Article : Google Scholar : PubMed/NCBI
19	Meler E, Figueras F, Bennasar M, Gomez O, Crispi F and Gratacos E: The prognostic role of uterine artery Doppler investigation in patients with severe early-onset preeclampsia. Am J Obstet Gynecol. 202:559.e1–559.e4. 2010.PubMed/NCBI
20	Ohkuchi A, Hirashima C, Matsubara S, et al: Alterations in placental growth factor levels before and after the onset of preeclampsia are more pronounced in women with early onset severe preeclampsia. Hypertens Res. 30:151–159. 2007. View Article : Google Scholar : PubMed/NCBI
21	Wikström AK, Nash P, Eriksson UJ and Olovsson MH: Evidence of increased oxidative stress and a change in the plasminogen activator inhibitor (PAI)-1 to PAI-2 ratio in early-onset but not late-onset preeclampsia. Am J Obstet Gynecol. 201:597.e1–597.e8. 2009.PubMed/NCBI
22	Kobayashi J, Yamada S and Kawasaki H: Distribution of vitronectin in plasma and liver tissue: relationship to chronic liver disease. Hepatology. 20:1412–1417. 1994. View Article : Google Scholar : PubMed/NCBI
23	Aaboe M, Offersen BV, Christensen A and Andreasen PA: Vitronectin in human breast carcinomas. Biochim Biophys Acta. 1638:72–82. 2003. View Article : Google Scholar : PubMed/NCBI
24	Chauhan AK and Moore TL: Presence of plasma complement regulatory proteins clusterin (Apo J) and vitronectin (S40) on circulating immune complexes (CIC). Clin Exp Immunol. 145:398–406. 2006. View Article : Google Scholar : PubMed/NCBI
25	Li DQ, Lundberg F and Ljungh A: Binding of vitronectin and clusterin by coagulase-negative staphylococci interfering with complement function. J Mater Sci Mater Med. 12:979–982. 2001. View Article : Google Scholar : PubMed/NCBI
26	Preissner KT: Structure and biological role of vitronectin. Annu Rev Cell Biol. 7:275–310. 1991. View Article : Google Scholar : PubMed/NCBI